FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:666-668 March 7, 1996 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Woolf, S. H.

To the Editor: Woolf's review (Nov. 23 issue)¹ of screening for cancer with prostate-specific antigen (PSA) omits important findings. He states that PSA testing could cost billions of dollars but does not mention that treating advanced prostate cancer is far more costly than treating early disease.

Woolf questions the importance of the spread of cancer beyond the prostate gland because extraprostatic extension has been reported in autopsy studies; however, the spread of cancer is associated with bad outcomes.² Findings in autopsy series are not representative of those in the general population. It cannot be assumed that a tumor with adverse . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.